<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558284</url>
  </required_header>
  <id_info>
    <org_study_id>STO-010</org_study_id>
    <secondary_id>2011-002657-60</secondary_id>
    <nct_id>NCT01558284</nct_id>
  </id_info>
  <brief_title>The Effect of Neu-P11 on Symptoms in Patients With D-IBS</brief_title>
  <acronym>Neu-P11</acronym>
  <official_title>Clinical Study on the Effect of Neu-P11 on Symptoms in Patients With Diarrhea- Irritable Bowel Syndrome (D-IBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placebo controlled double-blind study with 40 patients who have an diarrhea-predominant IBS,&#xD;
      20 get Neu-P11, 20 get a placebo. Neu-P11 is a, Melatonin receptor-, Serotonin 5-HT- 1A and&#xD;
      5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to test a possible beneficial effect of NEU-P11 in patients with IBS.&#xD;
&#xD;
      The effect on symptoms will be rated by symptom scores. The primary endpoint will be the&#xD;
      symptomatic benefit reported by the patient answering the simple question: Did your symptoms&#xD;
      improve compared to prior to the clinical trial.&#xD;
&#xD;
      Additional secondary endpoints will capture sleep quality, changes in stool texture and&#xD;
      individual symptom scores employing standardized symptom scores.&#xD;
&#xD;
      The study design is a 4 week, randomised, placebo-controlled, double blind study where 40&#xD;
      patients receive either placebo (20) or NEU-P11 (20). In the mid of the four week time of the&#xD;
      Study the dose can be doubled of the patient does not recognize any relief of the D-IBS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The relief of symptoms of the D-IBS by the study medication.</measure>
    <time_frame>after each week for the time of study</time_frame>
    <description>Only one question at the end of each visit and of each telephone call</description>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Diarrhea- Irritable Bowel Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neu-P11</intervention_name>
    <description>Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist</description>
    <other_name>there are no other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <other_name>there are no other names</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diarrhea-praedominant Irritated Bowel Syndroms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects age 18-80 years old&#xD;
&#xD;
          2. Male or female&#xD;
&#xD;
             Women of childbearing potential must have a negative pregnancy test at the screening&#xD;
             visit, on Day 1 of each treatment period, and use a reliable method of contraception&#xD;
             during the entire study duration and for at least 3 months after study drug intake.&#xD;
             Reliable methods of contraception are:&#xD;
&#xD;
               -  oral contraception&#xD;
&#xD;
               -  Double barrier type devices (e.g., male or female condom, diaphragm,&#xD;
                  contraceptive sponge) only in combination with a spermicide.&#xD;
&#xD;
               -  Intra-uterine devices in combination with a spermicide. Abstention, rhythm&#xD;
                  method, and contraception by the partner alone are not acceptable methods of&#xD;
                  contraception. Women not of childbearing potential are defined as postmenopausal&#xD;
                  (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.&#xD;
&#xD;
          3. Subject has IBS confirmed by the Rome III diagnostic criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has current evidence of duodenal ulcer, gastric ulcer, diverticulitis, or&#xD;
             infectious gastroenteritis.&#xD;
&#xD;
          2. Subject has a history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative&#xD;
             colitis, celiac disease), GI malignancy, GI obstruction, gastroparesis, carcinoid&#xD;
             syndrome, pancreatitis, amyloidosis or ileus&#xD;
&#xD;
          3. Subject is a candidate for GI surgery or has a history of GI surgery except&#xD;
             appendectomy and cholecystectomy.&#xD;
&#xD;
          4. Subject has psychiatric disorders which are not controlled (based on the investigator&#xD;
             medical judgment); subject with psychosis are excluded regardless of current therapy.&#xD;
&#xD;
          5. Subject has current or recent history (within 12 months of signing on informed&#xD;
             consent) of drug or alcohol abuse.&#xD;
&#xD;
          6. Subject is pregnant or lactating&#xD;
&#xD;
          7. Subject has history of human immunodeficiency virus (HIV) or hepatitis (B or C)&#xD;
&#xD;
          8. Subject has any condition or circumstance that could cause noncompliance with&#xD;
             treatments or visits&#xD;
&#xD;
          9. Subject has active malignancy within the last 5 years.&#xD;
&#xD;
         10. Subject taking antipsychotic drugs, antispasmodics, antidiarrheals (e.g. loperamide,&#xD;
             lubiprostone and bismuth subsalicylate), narcotics, prokinetic drugs, drugs indicated&#xD;
             for IBS (e.g Alosetron), or warfarin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Storr, Prof Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Klinik 2 LMU Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Grosshadern Medizinische Klinik 2</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Storr M. [Therapy of gastroesophageal reflux disease (GERD)]. Med Monatsschr Pharm. 2011 Dec;34(12):446-54; quiz 455-6. Review. German.</citation>
    <PMID>22233024</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Martin Storr</investigator_full_name>
    <investigator_title>Prof Dr.</investigator_title>
  </responsible_party>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Neu-P11</keyword>
  <keyword>Melatonin</keyword>
  <keyword>D-IBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

